For research use only
| Cat No. | ABC-TC3886 |
| Product Type | Bone Marrow Mononuclear Cells |
| Cell Type | Mononuclear Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Mantle Cell Lymphoma |
| Storage | Liquid Nitrogen |
Human Mantle Cell Lymphoma Bone Marrow Mononuclear Cells (Relapsed/Refractory) enable hematologic cancer modeling and translational immunology studies.
Human mantle cell lymphoma bone marrow mononuclear cells (Relapsed/Refractory) are derived from the bone marrow of patients who have failed standard therapies, reflecting a highly resistant and progressive disease state. These cells typically exhibit small to medium-sized lymphocytes with irregular nuclei, and condensed chromatin. They exhibit dysregulated cell cycle progression, impaired apoptosis, and sustained survival signals, contributing to therapy resistance. Human Mantle Cell Lymphoma Bone Marrow Mononuclear Cells express pan-B-cell markers (such as CD19, CD20, CD22). The cells are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | Human Mantle Cell Lymphoma Bone Marrow Mononuclear Cells (Relapsed/Refractory), MCL BM-MNCs (RR), Relapsed MCL Bone Marrow MNCs, Refractory Mantle Cell Lymphoma BM Cells |
| Species | Human |
| Cat.No | ABC-TC3886 |
| Product Category | Primary Cells |
| Size/Quantity | 1 vial |
| Cell Type | Mononuclear Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Mantle Cell Lymphoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Bone Marrow Mononuclear Cells |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
Human Mantle Cell Lymphoma Bone Marrow Mononuclear Cells (Relapsed/Refractory) serve as a critical ex vivo model for studying disease progression, drug resistance mechanisms, and novel therapeutic strategies. These cells are widely used in preclinical research to evaluate the efficacy of targeted therapies, including Bruton’s tyrosine kinase (BTK) inhibitors, BCL-2 antagonists, and proteasome inhibitors.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).